Literature DB >> 8569983

Urinary excretion of free cystine and the tiopronin-cysteine-mixed disulfide during long term tiopronin treatment of cystinuria.

A Lindell1, T Denneberg, J O Jeppsson.   

Abstract

We report the results of a biochemical evaluation of long-term treatment of cystinuria with the SH compound tiopronin (2-mercaptopropionylglycine). The effects of tiopronin were studied by monitoring the urinary excretion of free cysteine and the mixed disulfide between tiopronin and cysteine. Thirty-one patients with homozygous cystinuria were treated with tiopronin for 0.4-12 years (mean 7.8 years). The urinary concentration of free cysteine was used to adjust the tiopronin dose. In 28 of the 31 patients a mean urinary cystine concentration of less than 1,200 mumol/1(288 mg/l) was achieved with the final dose. The final daily doses of tiopronin ranged from 250 mg (1.5 mmol) to 3,000 mg (18.4 mmol; mean 1,540 mg; 9.4 mmol). In a majority of the patients the treatment reduced the 24-hour urinary free cystine excretion effectively, on average by 0.61 mumol (0.15 mg)/mg of tiopronin administered. No changes in the efficacy of tiopronin over time were observed, and the frequency of adverse effects was acceptable. To evaluate the effects of tiopronin on the metabolism of cystine we calculated the total urinary excretion of cystine as the sum of free cystine and the amount of cystine corresponding to the cysteine content of the tiopronin-cysteine disulfide. At low doses of tiopronin there was an increase in urinary excretion of the mixed disulfide as well as of total cystine. Monitoring urinary cystine concentration is necessary to achieve adequate individualized doses of tiopronin. Assessment of the mixed tiopronin-cysteine disulfide and the urinary excretion of total cystine shows that tiopronin may interfere with cystine metabolism in a more complex way than through a simple disulfide exchange reaction with urinary cystine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569983     DOI: 10.1159/000188740

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds.

Authors:  Erik Fjellstedt; Lotta Harnevik; Jan-Olof Jeppsson; Hans-Göran Tiselius; Peter Söderkvist; Torsten Denneberg
Journal:  Urol Res       Date:  2003-10-25

2.  A phase I clinical trial of tiopronin, a putative neuroprotective agent, in aneurysmal subarachnoid hemorrhage.

Authors:  Grace H Kim; Christopher P Kellner; Zachary L Hickman; Brad E Zacharia; Robert M Starke; Brian Y Hwang; Andrew F Ducruet; Luis Fernandez; Stephan A Mayer; Kevin J Tracey; E Sander Connolly
Journal:  Neurosurgery       Date:  2010-07       Impact factor: 4.654

3.  Cystine crystal volume determination: a useful tool in the management of cystinuric patients.

Authors:  Michel Daudon; Fabrice Cohen-Solal; Frédéric Barbey; Marie-France Gagnadoux; Bertrand Knebelmann; Paul Jungers
Journal:  Urol Res       Date:  2003-05-14

4.  Thiol antioxidants protect human lens epithelial (HLE B-3) cells against tert-butyl hydroperoxide-induced oxidative damage and cytotoxicity.

Authors:  Annalise Pfaff; Anna Chernatynskaya; Hannah Vineyard; Nuran Ercal
Journal:  Biochem Biophys Rep       Date:  2022-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.